Chelsie Derman

A 4.5 mm cut-off using the Skin Prick Automated Test showed comparable accuracy to the standard skin prick test in detecting birch pollen and house dust mite allergies.

This month in review spotlights 6 headlines, from the FDA approving sebetralsta for HAE to NICE Recommending Betula Verrucosa for Birch Tree Allergy.

Three-year PIONEER data show avapritinib provides lasting symptom relief in indolent systemic mastocytosis with good safety.

An online course, AllergyAware, significantly improved school personnel’s ability to recognize and manage anaphylaxis.

A new study found patients with HS are significantly more likely to develop new-onset depression and anxiety, regardless of disease severity.

A randomized trial found pharmacist-led counseling improved allergic rhinitis symptom control but did not enhance adherence, knowledge, or quality of life.

New data revealed that sleep impairment, especially daytime dysfunction, short duration, and sleep disturbances, is linked to increased diabetes distress.

Phase 4 trial shows esketamine provides significant symptom relief in patients with treatment-resistant depression within 24 hours of the first dose.

Anti-TNF therapies show strong 3-year durability in pediatric IBD, with new clinical markers helping predict early nonresponse in Crohn’s disease and UC/IBD-unclassified cases.

A new study highlights stress, concussion, and other early-life factors as key contributors to pediatric pain-predominant DGBIs.

A new study found older adults with insomnia experience significantly greater and longer-lasting depressive symptoms after inflammatory exposure.

New research finds patients with severe allergic asthma had greater emotional regulation than those with venom anaphylaxis, despite reporting poorer physical well-being.

A new analysis found a 0.78% prevalence of CSU in US adults, exceeding earlier estimates, and revealed significant mental, physical, and work-related burdens.

In children with mild immediate or delayed reactions, direct drug provocation testing may eliminate the need for painful skin tests, according to new data from Türkiye.

Study finds monthly HAE attacks dropped from 54% to 9.8% after 3 years of lanadelumab, with improved quality of life and reduced severity.

The National Institute for Health and Care Excellence endorses betula verrucosa for long-term relief from severe birch tree allergies, such as allergic rhinitis or conjunctivitis.

A new study showed that cashew-induced anaphylaxis mostly affects children under 5 years, often from tiny amounts that are under a teaspoon.

Patients with hereditary angioedema who switched to donidalorsen saw significantly fewer attacks and improved disease control. The FDA decision expected in August 2025.

A 2-step direct amoxicillin challenge safely ruled out penicillin allergy in low-risk pregnant patients, offering a faster alternative to skin testing.

Psychiatrists at the 2025 So Cal Psych Conference shared evidence-based tools and therapies to improve mental health outcomes for new mothers.

Neffy showed fast symptom resolution in children experiencing moderate anaphylaxis following oral food challenges, offering a needle-free alternative to epinephrine injection.

Daily intake of baked milk significantly improved tolerance and immune markers in young children with baked milk tolerance, according to a 12-month study.

Shaker shares how allergist-immunologists can use brief CBT, motivational interviewing, and risk reframing to shift patients’ fear of their food allergies into confidence.

Contrary to earlier research, a Framingham Heart Study analysis found no significant dementia risk tied to transient ischemic attack over 2 decades.

Transcend Therapeutics' TSND-201 gains FDA Breakthrough Therapy designation, offering new hope for rapid PTSD treatment with promising clinical trial results.

Johnson & Johnson seeks FDA approval for lumateperone (CAPLYTA) to significantly reduce schizophrenia relapse risk. Company submits an sNDA.

Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.

In ARRECTOR, patients reported symptom relief and improved quality of life as early as week 2, with strong tolerability and safety through week 8.

Phase 3 trials have shown low rates of serious adverse events with ruxolitinib cream in pediatric and adult patients with atopic dermatitis and non-segmental vitiligo.

5 FDA updates in psychiatry from the first half of 2025, plus other pipeline developments in psychiatry for depression, schizophrenia, and OUD.